Rocket Lab's Two-Speed Reality: The Backlog Is Booming While the Chart Keeps Sliding

Rocket Lab's revenue soars 62% to $234M, but shares fall 59% from high amid dilution fears from $1.944B Iridium acquisition.

There are moments when a company's operational story and its stock market story seem to be written by different authors. Rocket Lab is living through one of those moments right now, with record demand, a tightening merger timeline, and a share price that keeps drifting lower.

The disconnect is stark. The company's second-quarter revenue climbed 62 percent to $234 million, while its backlog swelled 137 percent year over year to $2.36 billion. Management has guided to third-quarter revenue between $250 million and $265 million, with GAAP gross margins of 29 to 31 percent. Yet the stock sits roughly 59 percent below its 52-week high of $133.80, trading at $54.70 and well under its 200-day moving average of $69.42. Over the past seven trading sessions alone, the shares have shed 6.7 percent, and the year-to-date decline stands at 11 percent.

The Iridium Deal Moves Closer to the Finish Line

Much of the market's caution traces back to the pending $1.944 billion acquisition of Iridium, a transaction that is now clearing its regulatory hurdles in quick succession. The Hart-Scott-Rodino antitrust waiting period expired on August 12, satisfying a key condition for closing. Rocket Lab subsequently filed an S-4 registration statement with the SEC to register the securities component of the deal, and the company — together with Iridium — has asked the Federal Communications Commission to approve the transfer of licenses and authorizations. Iridium shareholders are scheduled to vote on the combination on September 24.

To fund the cash portion of the deal and pay down debt, Rocket Lab has established an equity distribution program with Deutsche Bank Securities and Wells Fargo Securities worth up to $1.944 billion. That share placement program is the crux of investor anxiety: the dilution from a multi-billion-dollar equity raise is weighing more heavily on the stock than the operational momentum.

A Framework Contract Is Not the Same as a Contract

The recent flurry of government-related announcements has added to the narrative, though one in particular deserves a closer read. Rocket Lab's inclusion in the Space Force's NITE-STAR program — a framework with a total ceiling of $981 million for space testing and training infrastructure — is a significant milestone, but it is not a guaranteed revenue stream. The ceiling is shared among multiple contractors, and Rocket Lab's participation means it is now eligible to bid on individual task orders. It is a door opener, not a purchase order.

More concrete wins have followed. The US Space Force selected Rocket Lab for the Space Data Network Consortium and awarded $12 million in contracts for a global military communications network. Viasat has also tapped the company to build a satellite bus for the Protected Tactical SATCOM-Global program. And the 93rd Electron mission, launched on August 20, successfully deployed an Earth observation satellite for Japan's Institute for Q-shu Pioneers of Space — the ninth QPS-SAR delivery for that customer and the 14th launch of the year.

Reading the Insider Sales Correctly

The Form 144 filings that surfaced in late August might look alarming at first glance. CFO Adam C. Spice, President Marvin Bradford Clevenger, and COO Frank Klein were among five executives who sold roughly 78,800 shares worth $5.49 million. Klein separately disclosed a planned sale of about 35,500 additional shares valued at $2.35 million.

But these were non-discretionary sell-to-cover transactions, executed under pre-arranged plans to satisfy tax obligations from vesting RSUs. The executives retained 97.5 percent of their holdings after the sales — hardly the behavior of a management team losing faith in its own stock. Routine as they are, such filings tend to generate more noise than signal.

More telling, perhaps, is the institutional interest that has emerged despite the share price weakness. Capstone Investment Advisors built a new $1.56 million position in the second quarter, suggesting that at least some professional investors see value in the current levels.

The Bigger Picture: Growth Before Profitability

Rocket Lab's situation encapsulates a broader tension in the New Space sector. The company is delivering technologically — launching rockets on a near-weekly cadence and industrializing its manufacturing processes — but it is not yet consistently profitable. On an adjusted EBITDA basis, the company posted a loss of $8.8 million in the second quarter, and media reports indicate revenue fell short of expectations. Management has countered that more than $1 billion in new orders have been signed since the quarter closed, underscoring that demand remains robust even if revenue conversion takes time.

The stock's 19 percent discount to its 50-day average of $67.16 reflects a market that is increasingly impatient with the growth-before-profitability model. The Neutron program — Rocket Lab's answer to reusable rockets from competitors — remains on track for a launch pad target in the fourth quarter of 2026, though the window for this year is tightening. A successful Neutron debut would go a long way toward closing the gap between operational excellence and market confidence.

For now, investors are left weighing a merger that is advancing on schedule, a backlog that keeps growing, and a share price that keeps falling. The operational story and the market story will eventually have to converge — the question is which one moves first.